DexCom had three patents in mobile during Q1 2024. DexCom Inc has filed a patent for systems and methods that integrate a continuous glucose sensor with a receiver, medicament delivery device, controller module, and optional single point glucose monitor. Integration can be done manually, semi-automated, or fully automated. GlobalData’s report on DexCom gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
DexCom grant share with mobile as a theme is 33% in Q1 2024. Grant share is based on the ratio of number of grants to total number of patents.
Recent Patents
Application: Time averaged basal rate optimizer (Patent ID: US20240001032A1)
The patent filed by DexCom Inc. describes systems and methods for integrating a continuous glucose sensor with a receiver, medicament delivery device, controller module, and optional single point glucose monitor. The integration can be manual, semi-automated, or fully automated. The patent also outlines a method for optimizing a basal rate for continuous insulin therapy, involving providing a determined basal rate from a control algorithm, updating the rate based on continuous glucose sensor data analysis, and adjusting the rate in real-time based on glucose sensor data to manage hyperglycemia or hypoglycemia. The method includes pre-programmed basal rates, iterative updating, time-averaging analysis, and controlling insulin delivery within specific limits.
The patent further includes claims for a non-transitory computer-readable medium with instructions for the method, a display device with processors to execute the method, and a medicament delivery pump configured to deliver medication based on the determined basal rate. The display device and pump can trigger updates based on recognized patterns in the data, allow for user-selected basal rate profiles, and control insulin delivery within specified limits. The processor module in the medicament delivery pump can also manage insulin delivery rates over different time blocks and ensure control within upper and lower limits. Overall, the patent focuses on optimizing basal rates for insulin therapy through real-time adjustments based on continuous glucose sensor data, providing a comprehensive system for managing glucose levels effectively.
To know more about GlobalData’s detailed insights on DexCom, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies across the world’s largest industries.
